---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266916"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:24:43.968990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q3 net loss $29.9M; cash $274.9M; dabogratinib trials on track

## Summary
- Cash, equivalents, and marketable securities of $274.9M as of Sep 30, 2025; runway through at least 2027.
- Q3 net loss $29.9M vs $24.0M in Q3 2024; R&D spend $25.5M (up from $22.7M) on trial initiations.
- First patients dosed in Phase 2 achondroplasia (BEACH301) and NMIBC (SURF302) studies; interim data expected 2026.
- FDA cleared IND for dabogratinib in low-grade upper tract urothelial carcinoma (SURF303); Phase 2 start in 2026.
- Upcoming milestones: SURF302 3-month CR data in 1H 2026; BEACH301 safety sentinel results in 2H 2026.

## SEC filing metadata
- accession: 0001193125-25-266916
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/0001193125-25-266916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/tyra-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266916
- JSON: https://secwatch.observer/filing/0001193125-25-266916.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.